Monitoring of the Influence of Approved PH-therapies RV-PA Coupling

The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension. The main question it aims to answer is:

• Course of afterload and intrinsic contractility throughout the hospital stay Participants will be equipped with a device for continuous monitoring and recording of the right ventricular pressure signal.

Study Overview

• Status: Recruiting
• Conditions: Pulmonary Hypertension

Detailed Description

Pulmonary hypertension (PH) arises as a result of a vascular pathology affecting the pulmonary vessels, leading to an increase in resistance within the pulmonary circulation. The ability of the right ventricle to adapt to the elevated pressures caused by increased afterload is crucial for the progression and symptoms of the disease. This adaptation of the right ventricle to its afterload is referred to as ventriculoarterial coupling or RV-PA coupling, described by the ratio of contractility to afterload. Invasive pressure-volume loops (PV loops) are the gold standard for assessing RV-PA coupling. The loss of RV-PA coupling is considered a crucial factor in the development of right heart failure, the leading cause of mortality in patients with pulmonary hypertension. Therefore, reliable assessment of right cardiac function is essential for physicians to make informed decisions regarding further invasive diagnostics or therapy adjustments. Approved medications for the treatment of pulmonary arterial hypertension primarily induce pulmonary vasodilation, leading to a reduction in right ventricular afterload. The effects on right ventricular contractility and function, as represented by RV-PA coupling, are currently poorly understood and may not be consistent. In this study, 100 patients with PH requiring an inpatient stay for right heart catheterization will be equipped with a mobile, wireless system for invasive measurement of right ventricular pressure - the CorLog system (emka MEDICAL, Aschaffenburg, Germany). By combining continuously recorded pressure profiles with 3D echocardiographic volumetry, we will be able to generate PV loops and assess RV-PA coupling at various time points. The continuous monitoring of right ventricular pressure profiles throughout the entire hospital stay will allow us to capture the effects of newly initiated or expanded pulmonary vascular therapy on RV-PA coupling not only immediately but over several days. Furthermore, the 3D echocardiographic datasets will be analyzed using specialized software (ReVISION®, Argus Cognitive, Inc, Lebanon, NH) to mechanistically quantify the right ventricular contraction pattern and capture the immediate impact of pulmonary vasoreactive therapy on it. Additionally, a data pool will be created to validate the calculation of ejection fraction and RV-PA coupling based solely on pressure signals.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Khodr Tello, MD; Phone Number: +49 (0)641 985 56022; Email: khodr.tello@innere.med.uni-giessen.de

Study Locations

• Germany
  • Hesse
    • Giessen, Hesse, Germany, 35392
      • Recruiting
      • Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL)
      • Contact: Khodr Tello, MD; Phone Number: +49 (0)641 985 56022; Email: khodr.tello@innere.med.uni-giessen.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study population includes patients with pre-capillary pulmonary hypertension (Nice classification groups 1, 3, or 4) who are scheduled to undergo right heart catheterization for clinical reasons as part of invasive diagnostics for:

1. Establishing a diagnosis when there is a non-invasive suspicion of pulmonary hypertension.
2. Performing invasive hemodynamic assessment in patients already receiving vasoactive therapy, with the question of therapy escalation, particularly in cases of right cardiac decompensation.

Description

Inclusion Criteria:

• Initial diagnosis of PH (treatment-naive incident PH) of the Nice classifications 1 (PAH), 3 (PH related to lung diseases/hypoxia), and 4 (CTEPH), or known PH under ongoing vasoreactive therapy
• No contraindications for right heart catheterization, conductance catheterization, or CorLog implantation
• Written consent from the patient or their legal guardian

Exclusion Criteria:

• Absence of written consent
• Invasive exclusion of PH
• Age < 18 years
• Presence of contraindications for right heart catheterization, conductance catheterization, or CorLog implantation
• Pregnancy or breastfeeding

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Afterload	Responce of afterload (calculated from PV loops [Ea]) afterload during hospitalization to the initiation or escalation of pulmonary vascular therapy	3-7days
Contractility	Response of contractility (calculated from PV loops [Ees]) during hospitalization to the initiation or escalation of pulmonary vascular therapy	3-7days
Coupling	Response of Coupling (calculated from PV loops [Ees/Ea]) during hospitalization to the initiation or escalation of pulmonary vascular therapy	3-7days
Validation of Echo/CorLog PV-Loops	Validation of Echo/Corlog-generated PV loops based on conductance catheter-generated PV loops	On first day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Validation of pressure-only methods	Validation of methods for calculating ejection fraction and RV-PA coupling using ventricular pressure signals	3-7days
Contraction patterns	Analysis of volumetric datasets of the right ventricle using ReVISION software. Isolated quantification of right ventricular systolic shortening along the ventricular axes in 3-dimensional space.	3-7 days

Collaborators and Investigators

• Sponsor: University of Giessen

Study record dates

Study Major Dates

• Study Start (Actual): February 13, 2023
• Primary Completion (Estimated): February 13, 2025
• Study Completion (Estimated): February 13, 2026

Study Registration Dates

• First Submitted: June 28, 2023
• First Submitted That Met QC Criteria: June 28, 2023
• First Posted (Actual): July 7, 2023

Study Record Updates

• Last Update Posted (Actual): July 7, 2023
• Last Update Submitted That Met QC Criteria: June 28, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: Monitoring; Pulmonary Hypertension; Right Ventricle; RV-PA Coupling
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary
• Other Study ID Numbers: 211/22

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No